European Myeloma Network Consensus Statement on Functional High-Risk Multiple Myeloma

Area of Science:

• Hematology
• Oncology
• Internal Medicine

Background:

• Multiple myeloma (MM) is an incurable blood cancer with diverse clinical manifestations.
• A subset of newly diagnosed MM (NDMM) patients, initially classified as low-risk, experience early progression.
• This early progression, termed functional high-risk (FHR) MM, leads to significantly shorter overall survival.

Purpose of the Study:

• To define functional high-risk multiple myeloma (FHR-MM) based on early treatment response.
• To discuss the underlying biology of FHR-MM.
• To propose strategies for improving outcomes in FHR-MM patients.

Main Methods:

• This is an European Myeloma Network (EMN) consensus statement.
• The study defines FHR-MM as progression within 18 months of first-line therapy without high-risk cytogenetics.
• It reviews existing risk-stratification models and the role of novel agent induction response.

Main Results:

• Novel agent induction (NA-IND) response may be a more potent predictor of survival than initial diagnostic risk stratification.
• Early progression (within 18 months) in NDMM patients, irrespective of initial risk, identifies a group with poor prognosis.
• Functional high-risk (FHR) MM biology is distinct and requires further investigation.

Conclusions:

• Functional high-risk multiple myeloma (FHR-MM) is defined as early disease progression within 18 months of first-line therapy in the absence of high-risk cytogenetics.
• Response to novel agent induction (NA-IND) is a critical dynamic marker for identifying patients with poor prognosis.
• Further research into FHR-MM biology and development of improved therapeutic strategies are essential to enhance patient outcomes.